Summary
Signal counts
Assets tracked: 11
Watchlist assets: 8
Registry stop assets: 4
Sponsor overview
Pfizer
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00389441 | https://clinicaltrials.gov/study/NCT00051051 | https://clinicaltrials.gov/study/NCT01858389 | https://clinicaltrials.gov/study/NCT02159066 | https://clinicaltrials.gov/study/NCT00313768 | https://clinicaltrials.gov/study/NCT01684215 | https://clinicaltrials.gov/study/NCT01911273 | https://clinicaltrials.gov/study/NCT01430585 | https://clinicaltrials.gov/study/NCT00321815 | https://clinicaltrials.gov/study/NCT00471276 | https://clinicaltrials.gov/study/NCT01829217 | https://clinicaltrials.gov/study/NCT00556205 | https://clinicaltrials.gov/study/NCT00076011
Assets
Linked programs
- AG-013736: Low Signal (0/5)
- CI-1033: Results Not Found Signal (2/5)
- Dacomitinib: Watchlist Signal (2/5)
- LGX818: Watchlist Signal (2/5)
- paclitaxel + carboplatin + bevacizumab: Registry Stop Signal (4/5)
- PD-0332991: Low Signal (0/5)
- PF-03446962: Registry Stop Signal (4/5)
- PF-04691502: Registry Stop Signal (3/5)
- PF-3512676 + Erlotinib: Results Not Found Signal (2/5)
- sunitinib: Registry Stop Signal (4/5)
- Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor: Low Signal (0/5)